Dynavax Technologies Co. (NASDAQ:DVAX) Short Interest Down 6.3% in December

Dynavax Technologies Co. (NASDAQ:DVAX) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 16,780,000 shares, a decline of 6.3% from the November 30th total of 17,900,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the short-interest ratio is currently 8.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $12.77 on Thursday. The stock has a fifty day moving average price of $12.56 and a 200 day moving average price of $11.56. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $15.01. The firm has a market capitalization of $1.68 billion, a P/E ratio of 98.24 and a beta of 1.33.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of DVAX. GAMMA Investing LLC increased its position in Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the last quarter. US Bancorp DE grew its stake in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth $45,000. Nisa Investment Advisors LLC raised its position in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in Dynavax Technologies in the third quarter valued at $89,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.